{"entity":{"id":"imp1734","kind":"drug","name":"IMP1734","aka":[],"tldr":"IMP1734 is a small-molecule inhibitor from Eikon Therapeutics, in registered phase 2 trials for metastatic cancer.","summary":"IMP1734 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Eikon Therapeutics, in metastatic cancer. Described in the registry record as a parp1 selective inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of IMP1734","url":"https://clinicaltrials.gov/search?intr=IMP1734"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["eikon-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06253130"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"IMP1734","modality":"Small-molecule inhibitor","mechanism":"Described in the registry record as a parp1 selective inhibitor; the trial entries below carry the sponsor's wording.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/imp1734/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"eikon-therapeutics","kind":"company","name":"Eikon Therapeutics","route":"/companies/eikon-therapeutics/"}],"trial":[{"id":"nct06253130","kind":"trial","name":"A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors","route":"/trials/nct06253130/"}]}}